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Introduction
Bver the last several decades, the proportion of
persons incarcerated in the 9nited States has
been steadil; increasing. !he 9nited States
incarcerates the greatest number and the highG
est proportion of persons compared to an; other
countr; and b; midG;ear 2005, more than two
million persons were incarcerated in the 9nited
States, representing one in ever; 145 individuG
als.1 Studies have demonstrated that prior to
incarceration, persons engage in increased
rates of highGrisM behaviors including substance
use and risM; seN.2G6 In addition, there is a highG
er prevalence of *IP within the correctional setG
ting compared to the communit; among both
males and females.QG9 In a 199Q stud;, it was
estimated that approNimatel; oneGSuarter of all
*IPGinfected persons in the 9nited States
passed through the correctional s;stem in one
;ear.10 !he AIDS rate has been estimated to be
more than three times greater in prison than in
the communit;.11 !here are less data on the *IP
prevalence in Tails compared to prisons.
*owever, the estimated Tail *IP prevalence
rates range from 2.1G2.5U.12 Given high rates of
risM behavior in inmates and the increased *IP
prevalence rates behind bars, correctional *IP
testing programs provide an opportunit; for perG
sons at risM of infection to access *IP testing
services, education, and for *IPGinfected perG
sons to receive care. 
Persons entering correctional s;stems are often
marginalized in their communities due to factors
such as active substance abuse, mental health
disorders, and racial disparities relative to the
deliver; of health care.5,13 !his marginalization
leads to decreased access to health care in the
communit;. Incarceration, therefore, ma; be the
onl; chance for man; to access *IP testing serG
vices and have an opportunit; to receive *IP
care. !his ma; be particularl; true for racial and
ethnic minorities who are disproportionatel;
incarcerated in the 9nited States and are also
disproportionatel; infected with *IP.14
According to the Centers for Disease Control
and Prevention ZCDC[, blacMs and *ispanics
accounted for 48U and 18U respectivel; of all
*IP/AIDS cases diagnosed in 2005 in the 9S.15
Incarceration provides an opportunit; to interG
vene and provide *IP testing, medical care, and
linMage to *IP services upon release from the
correctional setting. 
Advantages to HIV Screening in Correctional
Settings
!here are uniSue advantages to correctional
*IP programs. 2hen incarcerated, health care
and prevention programs can be effectivel;
administered because clients are logisticall;
easier to access, clients are relieved from the
financial burdens of medical care, and at least
theoreticall;, are not engaged in ongoing risM
behavior.14 Correctional *IP testing programs
have the potential to increase the number of atG
risM persons tested for *IP as well as to
increase the number of persons who are aware
of their *IP serostatus. *IPGinfected inmates
can be educated about their infection, learn how
it is transmitted to others, and receive prevenG
tion counseling, and antiretroviral therap; can
be initiated when indicated. Addiction treatment
and mental health services can be provided in
conTunction with *IP care, which serves to
improve adherence with therap; both inside and
outside of the correctional environment. In addiG
tion, a detailed reentr; plan can be formulated to
linM the inmate to *IP clinical care, mental health
treatment, and substance use treatment in the
communit; upon release. ^urther, *IPGuninfectG
ed inmates can receive prevention counseling,
which ma; reduce their risM of subseSuent *IP
infection.
Critical to the implementation of a Sualit; corG
rectional *IP health program is a routine *IP
testing polic;. *IP testing is offered in all state
correctional s;stems within the 9nited States_
however, local policies t;picall; govern the manG
ner b; which testing is offered. Correctional testG
ing policies include Z1[ mandator; upon
entrance or eNit_ Z2[ routinel; offered, but not
mandator;_ Z3[ voluntar;, upon reSuest b; an
inmate_ Z4[ performed when clinicall; indicated,
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Dear Correctional Colleagues,
As the introduction to most ever; article on the topic of *IP in corrections is obliged to remind us, there
are a lot of people infected with the virus entering, living in and leaving our prisons and Tails.   !herefore,
it is not surprising to hear renewed calls for correctional facilities to become a centerpiece of a broad
effort to identif; persons unaware of their *IP infection.  !he Centers for Disease Control and Prevention
ZCDC[ recent recommendation that *IP testing be eNpanded to general healthcare settings has certainl;
fueled the latest interest in *IP screening in these settings and followGup CDC statements regarding
testing in correctional facilities are eNpected.
@o rationale individual can disagree that incarceration provides a valuable opportunit; to detect infecG
tious diseases such as *IP, other seNuall; transmitted diseases, latent tuberculosis and viral hepatitis.
Indeed, to not looM for such infections among incarcerated individuals in our countr; would smacM of calG
lousness and willful disregard.  
7ut, as alwa;s, the devil is in the details.  *ow and when should *IP screening be doneg %andator;
testing in prisons is not uncommon but raises important concerns regarding autonom;. Rapid *IP testG
ing seems well suited for Tails but some inmates are Tailed for less than 48 hours and are often inebriG
ated or intoNicated, maMing informed consent problematic. Is it best to test at entr; onl; or annuall; durG
ing incarcerationg  bogisticall;, widespread testing will draw personnel and resources from other valuG
able healthcare activities.  In addition, testing can be perceived as an unGfunded mandate with the cost
of testing itself and the eNpense of health care of those detected not t;picall; provided for b; those maMG
ing *IP testing recommendations.  !he cost of antiretroviral therap; for a small proportion of prison or
Tail inmates can strain the zeroGsum budgets of these facilities.  
!he man; facets of this topic are reflected in the perspectives and commentaries we have assembled
in this issue of the IDCR.  Drs. Curt 7ecMwith and %ichael PoshMus from Rhode Island have published
widel; on *IP screening in their state and provide their rationale for calls for rampedGup voluntar;, optG
out testing for *IP as part of a comprehensive program to manage *IP/AIDS in correctional settings.
Ravi favaser; and RicM Altice, %D both of hale offer their own view of the challenges to *IP screening
of inmates.  !opping off these thoughtful perspectives is a candid interview with Drs. ioe 7icM and David
Paar, eNperts in correctional healthcare, on their taMes on testing.   
Reading these articles, it becomes evident, even for someone such as m;self who feels that *IP testG
ing of persons in our Tails and prisons must be greatl; eNpanded, that the proposition is not a jslamG
dunMj.   Screening for *IP in Tails and prisons is a priorit; but has to be accompanied b; recognition that
additional cases of *IP infection will be detected and that these individuals will reSuire counseling, care
and referral.  If the CDCjs dreams of eNpanded testing are to be realized, state and federal support
needs to materialize.  Btherwise, we are left with wellGintentioned and Tustified recommendations that
we can argue over implementing but which do not lead to the reductions in new cases of *IP we can
all agree we want to see. 
David A. 2ohl, %D
Associate Professor of %edicine
Division of Infectious Diseases
AIDS Clinical Research 9nit 
!he 9niversit; of @orth Carolina G Chapel *ill
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as deemed b; the correctional medical staff_
and Z5[ ordered b; the court. %ost correcG
tional facilities offer *IP testing when
reSuested b; the inmate or when a clinical
s;ndrome consistent with *IP infection has
been identified.16 
Approaches to HIV Screening in Prisons
and Jails
Recentl; the CDC has issued recommendaG
tions for eNpanded *IP testing in health
care settings.  !he l;nchpin of these recomG
mendations is the proposal that *IP testing
be conducted for patients in all health care
settings after the patient is notified that testG
ing will be performed unless the patient
declines Zi.e. koptGoutk screening[.1Q 2e
strongl; support a universal, routine, optGout
*IP testing polic; in correctional settings
whereb; all inmates would undergo *IP
testing upon entrance to the correctional
facilit; unless declined. !he abilit; of the
inmate to decline testing is paramount
because optGout testing must be differentiatG
ed from mandator; testing. Routine optGout
testing has the advantages of decreasing
stigma associated with reSuesting an *IP
test and maMes *IP testing accessible to all
inmates. In an effort to improve the deliver;
of *IP testing services to those at risM of
infection, the CDC has also recommended
that voluntar; optGout *IP screening be perG
formed in correctional health care faciliG
ties.18 
%andator; *IP testing of inmates is perG
formed in a number of correctional instituG
tions. 2hile mandator; testing certainl;
accomplishes the obTective of increasing
testing among incarcerated individuals, we
favor a routine optGout polic; over mandatoG
r; testing given the advantages listed
above. 2e hope that correctional adminisG
trators and health care providers capitalize
upon the opportunit; that incarceration preG
sents b; engaging atGrisM persons who are
marginalized from the health care s;stem.
!he goal should be to provide highGSualit;
health care to individuals who cannot, or do
not, otherwise access it. !his includes a
comprehensive *IP counseling and testing
program that is accessible to all. 
Incarcerated persons should have the abiliG
t; to maMe health care decisions, such as
optingGout of an *IP test if the; so choose,
unless there is a court order den;ing them
of that right. *IP testing should not be puniG
tive. Rather, the deliver; of *IP and other
medical services to inmates should be a
component of the therapeutic and rehabiliG
tative services from which incarcerated indiG
viduals can benefit. 
7ecause all persons who enter the correcG
tional s;stem are, at one time or another,
held in a Tail s;stem, routine *IP testing in
Tails offers the most comprehensive
approach to *IP screening because screenG
ing at this point will reach the greatest numG
ber of people. *owever, Tails have rapid
turnover rates and short inmate sta;s, comG
plicating *IP screening efforts.16 2ith the
^ood and Drug Administration Z^DA[
approval of a variet; of rapid *IP tests, new
opportunities for correctional screening proG
grams have emerged. Rapid testing techG
nolog; provides definitive antibod;Gnegative
and preliminar; antibod;Gpositive test
results in approNimatel; 20 minutes. 
Although preliminar; positive rapid tests
need to undergo confirmator; western blot
testing, rapid test results can be delivered
immediatel; in conTunction with resultGspeG
cific postGtest counseling and risM reduction
interventions. !o promote Mnowledge of *IP
status among inmates, routine *IP testing
policies should be considered b; correctionG
al administrations and the utilization of rapid
*IP testing should be evaluated for use in
Tail settings.
Rapid *IP testing programs with pointGofG
care test result deliver; have been successG
ful in a number of nonGcorrectional settings
including labor and deliver;, communit; outG
reach programs, outpatient clinics and
emergenc; rooms.18G24 Rapid testing has
been shown to be preferred over standard
*IP testing among patients attending an
urgent care center due to results being
available within one testing session.25 In
the April 2006 issue of IDCR, the 7roward
Count; iail reported on its successes with
voluntar; rapid *IP testing in their Tail s;sG
tem.26 A pilot of stud; of rapid *IP testing
at the Rhode Island Department of
Corrections Tail demonstrated that rapid
testing was acceptable to Tail detainees,
was feasible to perform, and improved *IP
test result deliver;.2Q ^urther investigation
into the utilization of rapid *IP testing in the
Tail setting is needed including eNamination
of rapid testing: 1[ in facilities with different
*IP testing policies_ 2[ among male and
female inmates_ 3[ with respect to the influG
ence of rapid *IP testing on subseSuent
*IP risM behavior in the communit;_ 4[ in
conTunction with development of effective
*IP prevention programs for use in Tails_ 5[
with respect to cost effectiveness_ and 6[
with respect to safet; in reducing needleG
sticM eNposures among providers.
l2e strongl; support a univerG
sal, routine, optGout *IP testing
polic; in correctional settings
whereb; all inmates would
undergo *IP testing upon
entrance to the correctional
facilit; unless declined.m
An effective *IP testing polic; upon incarG
ceration is onl; appropriate if comprehenG
sive *IP clinical care services are provided
within the correctional facilit; after diagnoG
sis. !hese services should include a baseG
line medical evaluation with determination
of CD4n cell count and *IP plasma viral
load, initiation of antiretroviral therap; for
appropriate patients, proph;laNis of opporG
tunistic infections, and screening for other
conditions, including other seNuall; transG
mitted infections, tuberculosis, viral hepatiG
tis, drug addiction, and mental illness.
Paccination for hepatitis 7 virus should be
performed in all susceptible patients, given
the risM factors for hepatitis 7 virus infection
are identical to those for *IP infection.
^urthermore, *IP care providers worMing
inside a correctional setting must have
effective lines of communication developed
with communit;Gbased *IP providers so
ongoing treatment plans can be continued
inside and outside the correctional setting
with minimal interruption. !his communicaG
tion is critical to the ongoing care of persons
who continuall; c;cle through the correcG
tional s;stem. 
Conclusion
Incarceration is a realit; of our current TusG
tice s;stem. 7ut, incarceration brings with it
an opportunit; to engage our societ;js most
atGrisM individuals. 2e encourage and supG
port the development of comprehensive
correctional *IP programs that are comG
prised of the following elements: 1[ routine
voluntar; optGout *IP testing upon incarcerG
ation_ 2[ comprehensive medical evaluation_
3[ provision of *IP care during incarceraG
tion, and 4[ implementation of detailed reG
entr; practices that engage communit;
providers. ^urther worM is needed to maMe
this t;pe of program more prevalent across
the 9nited States. !his reSuires a multidisciG
plinar; effort with input from correctional
and communit; *IP providers, correctional
medical staff, administrators, correctional
officers, mental health providers, inmate
advocates, and discharge planning staff, to
name a few. !he goal is to promote *IP
education and health among our inmates
that translates into reduced *IP morbidit;
and mortalit; in our communities.
3
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Stop AIDS in Prison Act of 2007 is
approved by House Judiciary Committee
!he *ouse iudiciar; Committee recentl;
passed a bill that would establish *IP/AIDS
testing, treatment, and education programs in
all federal prisons.  !he bill, entitled the kStop
AIDS in Prison Act of 200Q,k is aimed at preG
venting the spread of the *IP, both within the
federal prison s;stem and the freeGcommuniG
t;, b; educating inmates on the virusjs modes
of transmission, prevention methods, treatG
ment, and disease progression.  Proposed
*IP/AIDS programs would conduct mandatoG
r; testing upon each inmatejs entr; to prison
and before their reentr; into the communit;,
but would allow inmates the option of declinG
ing testing unless the; are Mnown to have
been eNposed to the virus.  !he bill would
reSuire both pre and post test counseling for
inmates and mandates that inmates receive
their test results in a timel; manner.  Inmates
who test seropositive for *IP must be providG
ed with kcomprehensive medical treatmentk
during their incarceration, in addition to preG
release counseling and linMage to communit;
care after their release.  !he bill has ;et to be
scheduled for general debate in the *ouse.
Source: http://www.govtrack.us/congress
/bill.xpd?bill=h110-1943
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ROUTINE HIV TESTING IN JAILS: ADDRESSING THE CHALLENGES
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7ecause prisons and Tails house a populaG
tion facing a disproportionate share of the
burden of *IP infection and man; of whom
are unaware of their *IP status, these faciliG
ties serve as important sites for the testing
and treatment of *IP.1 Routine *IP testing
presents a promising opportunit; for correcG
tional institutions to provide individuals with
Mnowledge of their *IP status, education
and counseling services, and access to
treatment both within the correctional setting
and upon release into the communit;.
!raditionall;, prisons and Tails have operated
outside of the purview of our public health
infrastructure. Screening of *IP within these
settings provides an innovative approach to
facilitate communit;Gcorrectional linMages.  
iails are distinct from prisons due to their
high rate of turnover, var;ing states of intoNG
ication, lacM of uniform intaMe procedures,
and t;picall; brief lengths of sta;. In order to
implement successful routine *IP testing
programs in Tails, a number of logistical chalG
lenges must be properl; addressed before
implementation can be successful.  
A maTor challenge to implementing routine
*IP testing in Tails is choosing the optimal
time to conduct testing.2 Although immediG
ate testing at intaMe might confer the largest
public health benefit since man; inmates will
be released within the first few da;s of incarG
ceration, such a testing approach creates
additional logistical challenges.  2hile there
is never an ideal time to deliver kbad newsk,
the timing of delivering nonGemergent bad
medical news Zsuch as a preliminar; posiG
tive result in an as;mptomatic patient[ must
be carefull; considered.  @ewl; incarcerated
detainees eNperience high rates of suicidal
behavior, acute intoNication and abstinence
s;ndromes, and ps;chological distress at
the time of entr;.3,4 It is currentl; unclear
from the empirical literature if individuals
under such stresses have medical compeG
tence to kopt outk of routine testing.  If indiG
viduals do not kopt outk and are provided
with a kpreliminar; positivek despite their
fragile circumstances, the; are almost cerG
tainl; unprepared to consider and respond
to the conseSuences of a preliminar; posiG
tive *IP test result. 5, 6
l!he costs for providing care will
remain a concern in our nationjs
Tails.  iails are often under local
Turisdiction and resources are
often limited.m
It is daunting to imagine routine *IP testing
upon intaMe at some of the largest and
busiest Tails.  Several hundred people ma;
be processed dail;, with intaMe procedures
taMing place 24 hours a da;.  2hile routine
*IP testing might be sufficientl; managed, it
is often the case that staffing is suboptimal.
Adding *IP testing Zwith associate *IP
counseling for preliminar; positives[ will
reSuire additional inmate movement within
the facilit;, worMing with inmates in various
states of intoNication and withdrawal, and
sSueezing additional service reSuirements
into the alread;Glimited available time.  All of
this would have to be accomplished through
coordinated efforts with custodial staff who
t;picall; tr; to avoid an; unnecessar; moveG
ment within the facilit;.  
Bne of the unresolved issues for routine
testing in Tails is ensuring deliver; of confirG
mator; *IP test results for those who test
preliminaril; positive. Confirmator; test
results often reSuire up to a weeM to receive
and, given the high rates of release earl; in
the course of incarceration, man; individuG
als will be released without trul; Mnowing
their status.  Communit; public health s;sG
tems must be adeSuate to provide contact
tracing after release to ensure delivering
confirmator; results. ^or individuals who
remain incarcerated, additional resources
will be reSuired to provide routine and necG
essar; testing and provision of antiretroviral
medications if medicall; indicated.  
!he costs for providing care will remain a
concern in our nationjs Tails.  iails are often
under local Turisdiction and resources are
often limited.  Determining who will pa; for
testing, counseling, and treatment must also
be taMen into consideration. !he abilit; to
linM with public health and national health
care programs must be included_ not the
least of these is the %edicaid program.  
Prisons and Tails are eNcluded from both
general diseaseGspecific programs Zfunds
are channeled to public health departments
and publicl; run health care facilities[ and
third part; pa;ers Zinsurance, %edicare, and
%edicaid t;picall; stop upon confinement[.   
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Although government funded programs
such as %edicare, %edicaid and R;an
2hite subsidies eNist to offset the costs of
treatment, the incarcerated remain the onl;
demographic group in this countr; that is
broadl; and specificall; eNcluded from fedG
eral and state third part; coverage for their
care. Bn the other hand, local legislation
and other legal precedents at least tacitl;
reSuire that correctional facilities in the
9nited States provide the communit; stanG
dard of medical care for *IPGinfected
inmates.  Prisons and Tails alread; face sigG
nificant resource limitations in providing
eNisting medical services to their continuall;
increasing inmate population.  It is estimatG
ed that one Suarter of *IPGinfected individuG
als in the 9nited States pass through a corG
rectional facilit; ever; ;ear and it is believed
that an;where from one third to one half of
these persons are unaware of their *IP staG
tus.QG9 If this is indeed the case, then prison
and Tail administrators face a huge financial
disincentive for conducting widespread *IP
screening programs in their facilities.  
lSerious ethical considerations
are also raised when correcG
tional settings test individuals
for *IP and initiate treatment
without ensuring adeSuate folG
lowGup and treatment services
upon reGentr; into the communiG
t;.m
`Ntensive costGbenefit anal;ses support
eNpanded *IP screening in all settings
where the *IP seroprevalence of undiagG
nosed is greater than 1U.10, 11 In Tails, howG
ever, there is a political disincentive for corG
rectional administrators to be viewed as
providing care and spending scarce
resources on prisoners.  In the case of rouG
tine testing in Tails in the current funding
environment, Tails will bear the direct costs
of these programs but will not directl; reap
the benefits.  !he case for prisons ma; difG
fer as man; of these individuals are incarG
cerated for prolonged periods of time.  It will
therefore reSuire a shift in philosoph; b; Tail
administrators to promote a more societal
approach, perhaps with the assistance of
public health incentives and support. In
order for routine *IP testing to be adopted
b; Tails, the; must become part of the larger
public health infrastructure. 7; doing so, the
costs of screening and treatment could be
shared more globall; b; the rest of societ;.  
Programs that facilitate linMage to communiG
t;Gbased treatment for *IPGinfected prisonG
ers are another important challenge that
must be addressed for Tail screening to be
successful. As marginalized members of
societ;, those with criminal records do not
enTo; stead; access to health care in the
communit; and some are chronicall; subG
Tected to episodic care.12 ^urthermore,
because of the high rate of recidivism
among the incarcerated, one of the maTor
challenges to treating *IPGinfected individuG
als is providing continuit; of care as the;
c;cle in and out of the correctional s;stem.
9nderstanding the effects of the unstrucG
tured interruptions in *AAR! care for these
individuals remains an important area of
stud;.13 Serious ethical considerations are
also raised when correctional settings test
individuals for *IP and initiate treatment
without ensuring adeSuate followGup and
treatment services upon reGentr; into the
communit;.  
Despite these obstacles, routine *IP testing
programs represent best public health pracG
tices and should be implemented. !he
authors are calling for review and considerG
ation not onl; of the implementation of
broad testing, but also for resolution of the
associated challenges.  2hile there are curG
rentl; initiatives to overcome these obstaG
cles, we still do not Mnow how to resolve
them all, even on a limited scale, much less
if testing were to become universal in Tails.
!he authors also want to underscore the
mounting need for a public health approach
to the deliver; of correctional health care,
including access to the general funding
mechanisms that serve so much of the
American public. 
Funding: !he authors would liMe to thanM
the @ational Institute on Drug  Abuse for
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To get their perspectives on the role of rou-
tine screening for HIV infection in correction-
al settings, IDCR intern Christine Devore
recently spoke with Dr. Joseph Bick, Chief
Medical Officer, California Medical Facility,
and Dr. David Paar, Associate Professor of
Medicine at the University of Texas.  
Christine Devore (CD): What do you see
as the most significant barriers to imple-
menting routine HIV testing in correction-
al facilitiesh
Dr. Joe Bick (JB): Bne of the first barriers
would be the enormous volume of inmates.
Bver three million Americans are currentl;
incarcerated and an estimated ten million
Americans enter and leave incarceration in
an; given ;ear, man; of whom have onl;
short sta;s in Tail or prison.  As a result, there
are man; logistical challenges to ensuring
routine testing in that t;pe of setting.
Incarcerated persons are moved freSuentl;
and such moves are not alwa;s coordinated
between custod; and medical s;stems.
!r;ing to Meep tracM of people as the; move
through the penal s;stem can be difficult.
%aMing *IP testing routine has maTor worMG
load implications for correctional staff, as
care providers must ensure that ever; inmate
who undergoes *IP testing is provided with
pre and postGtest counseling.  `nsuring that
ever; person who tests positive has access
to *IP Mnowledgeable providers will be diffiG
cult for man; correctional facilities.  Another
perceived barrier is the associated cost of
*IP testing and counseling.  2hile increased
testing will certainl; lead to a decrease in
morbidit; and mortalit;, prevention of costl;
hospitalizations, and decreased risM of further
transmission of *IP, the individual Tail or
prison ma; not feel the effects of these beneG
fits.
David Paar (DP): I gave a talM last fall about
the CDCjs guidelines at a correctional meetG
ing that included people from the communit;
who provide services to inmates in prisons.
%an; of these worMers were ver; concerned
about implementing these guidelines in the
prison.  Some thought that prisons should not
viewed as a health care setting, while others
thought it would be logisticall; impossible for
most prisoners to give informed consent if the
CDC guidelines were implemented.  !hat
being said, Ijm in favor of the CDCjs new testG
ing policies.  I believe that these policies can
and should be implemented.  I thinM it is best
to test prisoners upon intaMe, although the
volume of inmates being processed would
maMe testing difficult.
CD: Some states have laws or regulations
that dictate the HIV testing policies in pris-
ons and jails.  Does your state have any
laws that could pose as barriers to imple-
menting the CDC_s recommendationsh
JB: *IP testing regulations and laws var;
from state to state.  In California, there are
policies and laws that can serve as disincenG
tives for inmates to opt for *IP testing.  Some
of these laws can lead to restrictions on Tob
assignments, potential housing sites, and
educational opportunities for incarcerated
persons.  Inmates who are *IPn ma; be subG
Tect to harsher penalties if the; participate in
activities that involve sharing blood or bodil;
fluids than their *IP negative peers would
face.  Although some of the statejs regulaG
tions are valid and reasonable, the; can lead
to patients deciding to forgo voluntar; or optG
out testing.
DP: !eNas recentl; passed legislation that
would maMe *IP testing mandator; in prisons
on intaMe.  !eNas had previousl; held a polic;
of routine, optGout testing that was first impleG
mented in 1988. !eNas also passed legislaG
tion in the fall of 2005 that reSuired prisoners
to be tested before release.  Although few
new cases of *IP were discovered this wa;,
the program was wellGreceived b; inmates in
that there are no documented refusals for
testing that I am aware of.
CD: The CDC suggests that providers do
not need separate, written consent for HIV
testing.  Rather, fgeneral consent for
medical care should be considered suffi-
cient to encompass consent for HIV test-
ing.f  Do you feel that this form of consent
is appropriate in the correctional settingh
JB: %; personal opinion is that some t;pe of
written consent is still worthwhile in the corG
rectional setting.  !he process of being
booMed into a Tail or a prison can be an
eNtremel; disorienting eNperience for man;
people.  %an; of the inmates ma; be under
the influence of alcohol or drugs upon intaMe
and could be unsure as to what t;pes of medG
ical care and testing the; are allowed to
refuse.  As a result, some t;pe of separate
consent process for *IP testing is valuable if
we are going to trul; have informed consent
in the correctional setting.
DP: I believe that the longer and more comG
plicated the consent process, the less  numG
ber of people who are actuall; tested.  Bf
course, ever;bod; should be informed of
testing and understand whatjs going on.  In
!eNas, we use a polic; of oral consent for
testing.  Inmates donjt have to sign a consent
form_ we simpl; asM them if the; want to be
tested for *IP.  I thinM that allowing oral conG
sent could violate a personjs abilit; to give
proper consent if the process is done hastil;,
but we can also limit a personjs abilit; to conG
sent b; maMing the process overl; complicatG
ed with several forms.
CD: Could the CDC_s recommendations
for informed consent deepen feelings of
mistrust between correctional care
providers and their inmatesh
JB: I thinM so.  I believe that man; of our
patients are alread; distrustful of authorit;
and do not implicitl; understand that when we
asM them if we can provide general medical
care, that that also involves testing for *IP
and other seNuall; transmitted diseases.  I
thinM itjs valuable to have a separate converG
sation with each inmate to discuss wh; the;
should want to Mnow their *IP status, as well
as the possible benefits and outcomes of
testing.  !his process of gaining informed
consent can certainl; be streamlined, but I
feel that it is still valuable to Meep *IP testing
consent separate from consent for general
medical care.
CD: How do issues of confidentiality
affect HIV testing in the correctional set-
tingh 
JB: I thinM confidentialit; can be a significant
barrier to testing, both in the correctional setG
ting and in other settings.  Confidentialit; is
one of the reasons wh; anon;mous testing
elsewhere in the countr; has been so valuG
able.  Bnce a person tests positive in a corG
rectional setting or elsewhere, it automaticalG
l; signals a chain of events that a person canG
not control, including the possibilit; that those
results will impact access to worM, career
choice, health care insurance, and life insurG
ance.  
^or eNample, one challenge for our populaG
tion is the abilit; to afford a college education
after incarceration. In this countr;, man; peoG
ple Toin the militar; in order to be compensatG
ed for their education, but people who are
Mnown to be *IP positive are prohibited from
Toining the militar;.  As a result, inmates who
are concerned about the confidentialit; of
their *IP test results or of the impact of these
results on their future might refuse testing. @o
matter how hard we stress the issue of confiG
dentialit; in the correctional setting, itjs
impossible to have a diagnosis such as *IP
not be Mnown b; a significant portion of the
emplo;ees and residents of a correctional
facilit;. An inmatejs *IP serostatus becomes
part of both their medical file and custodial
file.  !heir status is considered in ever; deciG
sion about housing, programming, worM,
school, and release.  In addition, fellow
inmates are ver; adept at figuring out a perG
sonjs *IP status based upon what t;pe of
doctor an inmate sees, what medicines he
receives, and how often he receive mediG
cines.
DP: Confidentialit; is an issue that is imporG
tant to ever;bod;, both in and out of the corG
rectional setting.  In m; eNperience, most
inmates will often risM a breech of confidenG
tialit; in order to Mnow their own *IP status.
2hile maintaining confidentialit; is a maTor
priorit; for care providers, it is also ver; diffiG
cult to Meep a personjs *IP status confidential
in the correctional setting. %ost inmates recG
ognize and accept this risM when the; underG
go testing.  I donjt thinM that the implementaG
tion of the new guidelines, per se, will affect
confidentialit;.
CD: Patient mistrust of care providers is
often cited as a barrier to HIV testing and
treatment in the correctional setting.
What steps can correctional providers
take to alleviate these feelings of mis-
trusth
JB: !rust is not Tust a correctional issue.
!here a number of studies that demonstrate
that patientsj adherence to therap; is directl;
related to their belief that the therap; is going
to help them and their trust for their care
provider.  If ;oujre in an environment where
;ou thinM ;our provider is not *IP MnowlG
edgeable and ;ou donjt believe that the medG
icines themselves are going to be of an;
value, then ;ou have little incentive to get
tested. Patients should be educated as to
how the; can benefit from Mnowing their *IP
SPOTLIGHT: ROUTINE HIV TESTING IN THE CORRECTIONAL SETTING: AN INTERVIEW WITH
DR. JOE BICK AND DR. DAVID PAAR
Summer 200Q      Pol. 9, Issue 1Q visit IDCR online at www.IDCRonline.org
7
ROUTINE HIV TESTING IN THE CORRECTIONAL SETTING...
(continued "rom paDe =)
status b; decreasing their liMelihood to get
sicM and increasing their lifespan.
DP: I thinM itjs important for care providers to
demonstrate compassion in dealing with
inmates.  ^or eNample, care providers must
respect an inmatejs decision to refuse an *IP
test, as forcing a test would onl; engender
mistrust. I feel strongl; that inmates should
alwa;s have the right to optGout of *IP testG
ing.
CD: What do you think are the most
important steps for facilities to take in
implementing the CDC_s guidelines for
regular, mandatory opt-out HIV testingh
JB: I thinM itjs important for each correctional
s;stem to have an inGdepth conversation with
ever;one who will be impacted b; the CDCjs
guidelines, including medical staff, custod;
officers, inmates, and the pharmaceutical
staff.  !here is tremendous room for benefit
b; implementing guidelines, but also signifiG
cant opportunities for doing harm if the guideG
lines are not implemented in a thoughtful
wa;.  ^or eNample, if a facilit; implements
routine testing for inmates as the; leave the
facilities, it is liMel; that some of the inmates
who are tested will not receive their results.
%ost people assume that, if the; didnjt hear
an;thing about their test results, then the
results must have been good.  Patients could
then return to the communit; and unMnowingG
l; pass *IP to other people.
DP: ^irst of all, facilities must discern what
steps need to be taMen in order to implement
routine testing.  In most s;stems, this will
reSuire more than sending a memorandum
describing the needed changes.  
^acilities must reall; eNamine the recommenG
dations, understand them, and understand
what needs to be done to implement them.
^or eNample, facilities need to consider how
man; inmates the; intaMe, how man; blood
drawers the; have, and how man; counG
selors the; have.  ^acilities must then use
this assessment to prepare for a liMel;
increase in the number of inmates being testG
ed.
CD: The CDC recommends annual testing
for at-risk populations as a minimum.  Do
you feel that annual testing is appropriate
for incarcerated individualsh
JB: I would sa; that therejs ample evidence
that *IP transmission occurs in the correcG
tional setting, albeit in low levels.  !he overall
maTorit; of people leaving prison with *IP
were infected at entr;, although we do have
some data that demonstrates new cases of
*IPGinfection occurring during incarceration.
So I thinM that, at least in some select correcG
tional settings, it would be worthwhile to have
followGup, if not annual, testing.  !he most
costGeffective part of testing will be testing
people when the; enter the s;stem.  I do
thinM there is some additional benefit to testG
ing atGrisM individuals either at annual time
frames or at the time of release.
DP: I thinM annual testing is appropriate.  I
thinM eNactl; how ;ou target the katGrisMk popG
ulation is Suestionable.  Bbviousl;, facilities
can use selfGreported Suestionnaires to
determine individualsj behaviors that place
them at risM for *IP infection.  I thinM that proG
viding annual voluntar; testing for all inmates
might be easier than attempting to assess
which individuals are at risM.  ^acilities can
also offer some sort of *IP education proG
gram so that people Mnow what behaviors
can lead to infection.
CD: What are the greatest benefits to
implementing routine HIV testingh
JB: 2e Mnow that up to a Suarter of persons
infected with *IP donjt Mnow their serostatus
and that the prevalence among the incarcerG
ated population is five to ten times higher
than among general population.  2e also
Mnow that when routine optGout testing has
been implemented in corrections, inmates
have generall; accepted testing.  Inmates are
a highGrisM population, who might not have
tested in a setting outside of corrections.  As
a result, we have the opportunit; to test a
large population of at risM people who do not
Mnow their status. 
In addition, the available therapies can
decrease the liMelihood of a person becoming
sicM with opportunistic infection and can
eNtend their lives. !his has been demonstratG
ed both in the free communit; and correcG
tional setting.  2e have opportunit; to beneG
fit the particular individuals with *IP.  2e also
have the opportunit; to decrease transmisG
sion of *IP to seNual and drugGusing partG
ners.  bastl;, we have an opportunit; to save
the health care s;stem mone;.  People who
are diagnosed with *IP when the; present
with an AIDSGassociated infection or cancer,
cost the health care s;stem a lot of mone;.
So initiating treatment earlier can not onl;
benefit that person and an; people the;jve
infected, but the general health care s;stem
as well.
DP: !he statistics var;, but supposedl; a
Suarter of Americans living with *IP do not
Mnow that the; are *IP positive.
Incarceration provides a uniSue opportunit;
to educate, test, and treat atGrisM persons in
order to interrupt the *IP epidemic.
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Testing Consent Pre-test Counseling
*IP !esting Policies: A Comparison of @ew and Bld CDC Recommendations
Old Policy
Poluntar; testing provided as a routine part
of medical care.  !argeted testing encourG
aged on the basis of risM screening.
Old Policy
Specific consent for *IP testing reSuired.
Old Policy
Prevention counseling reSuired.
New Policy
Screening conducted after notif;ing the
patient that an *IP test will be performed
unless the patient declines ZoptGout
screening[ is recommended in all health
care settings.  Persons at high risM for
*IP should be screened at least annuall;.
New Policy
General informed consent for medical
care should be considered sufficient to
encompass informed consent for *IP
testing.
New Policy
Prevention counseling should not be
reSuired in the health care setting, but
should be strongl; encouraged for perG
sons at risM for *IP Ze.g., persons at S!D
clinics[.
Rationale
Screening for *IP has been proven to be
effective in identif;ing new cases of *IP
among pregnant women, while targeting
testing among all health care patients has
been relativel; unsuccessful.  %an; peoG
ple do not perceive themselves to be at
risM for *IP or do not disclose their risMs,
thereb; maMing targeted testing ineffecG
tive.
Rationale
!esting should onl; be undertaMen with
the patientjs Mnowledge and understandG
ing that *IP testing is planned.  Studies
indicate that patients are more liMel; to
consent to *IP testing if it is treated the
same as screening for an; other disease,
without special procedures such as writG
ten permission from the patient.
Rationale
*ealth care providers often cite timel;
and eNpensive preGtest counseling as a
barrier to *IP testing.  Patients should be
informed of what *IP infection is, the
meanings of positive and negative test
results, and should be offered an opporG
tunit; to asM Suestions.
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New Study Demonstrates Entecavir_s Activity in
Inhibiting Replication of HIVI-1, Raises
Concerns Regarding Resistance to Anti-HIV-1
Drugs
A new stud; found evidence that contradicts previG
ous findings that entecavir does not inhibit replicaG
tion of *IPG1 in clinicall; relevant doses.  !he stud;,
conducted b; researchers at the iohns *opMins
9niversit; School of %edicine and the *oward
*ughes %edical Institute, found that the drug, which
is used to treat chronic hepatitis 7 virus infection
Z*7P[, does indeed lead to 1Glog10 decreases in
*IPG1 R@A when administered in clinicall; relevant
doses.  !hese findings were based on a case stud;
of three *IP and *7PGinfected patients and includG
ed both an in vitro and in vivo anal;sis of the drugjs
effects. `ntecavir had previousl; been recommendG
ed for use in *IPG1 and *7P coinfected individuals
who reSuired treatment for *7P, but not *IPG1, as it
was not believed to inhibit replication of *IPG1 or
pose an; threat of causing antiG*IP drug resistance
in patients.  Researchers, however, also found that
entecavir could select the %184Q mutation and
thereb; confer a high level of resistance to the antiG
retroviral ZARP[ drugs lamivudine and emtricitabine
in some patients.  !his discover; suggests that preG
vious recommendations on the use of entecavir in
persons who are not being treated for *IPG1 should
be reconsidered in order to prevent resistance to
antiG*IPG1 treatment options.
In an editorial on this topic, Dr. %artin *irsch
eNplained that the difference in findings between the
two studies on entecavir as a replication inhibitor for
*IPG1 could be the result of a difference in the senG
sitivit; of the assa;s, virus strains, or amount of
virus used in each of the two studies.  In addition,
Dr. *irsch stated that guidelines for entecavirjs use
are now being reconsidered.  !he compan; that
manufacturers the drug has issued a letter to health
care providers to reiterate that the drug had not
been evaluated in coinfected patients who were not
simultaneousl; receiving *IPG1 treatment.  Also, the
Department of *ealth and *uman Services Panel
on Antiretroviral Guidelines for Adults and
Adolescents no longer recommends entecavir for
coinfected patients who are not also receiving antiG
*IPG1 treatment.
The HBV Drug Entecavir --- Effects on HIV-1
Replication and Resistance.  McMahon M. et al.
New England Journal of Medicine.  2007;356:2614-
21.
Entecavir Surprise.  Hirsch, Martin S.  New England
Journal of Medicine.  2007;356:2641-43.
Young Incarcerated Men_s Perceptions of and
Experiences with HIV Testing
An anal;sis of the formative research phase of
ProTect S!AR! ZS!D and AIDS RisM Reduction
!rials[ reveals former incarcerated menjs eNperiG
ences with and opinions of *IP testing, both inside
and outside the correctional setting. ProTect S!AR!,
which is funded b; the CDC, conducted both SualiG
tative and Suantitative faceGtoGface interviews with
105 men at 5 separate timeGintervalsGbefore each
prisonerjs release and 1 weeM, 1 month, 3 months,
and 6 months after release. !he interviews revealed
that, while nearl; all of the men had been tested for
*IP and most had been tested on multiple occaG
sions, the men had fairl; consistent themes in disG
cussing their reasons for getting tested, as well as
the barriers that the; encountered.  %ost men cited
their perceptions of testing being mandator;, conveG
nient, or free as factors in getting tested for *IP in
prison. Conversel;, the men consistentl; reported
lacM of health insurance, emplo;ment, and time as
barriers to testing outside of prison.
Also, man; men stated that the; onl; sought health
care in emergenc; situations and it did not occur to
them to get tested for *IP or even consider their risM
factors. Bther men reported that the; Mnew that
the; were at risM for *IP, but feared Mnowing their
*IPGstatus.  !he stud; also discussed the prevalent
perception that kno news is good news,k revealing
that most men believed themselves to be *IPGnegG
ative if the; did not receive their test results.  Bnl;
half of the men reported receiving test results and
most men did not receive posttest counseling.
!hese findings emphasize the need to strengthen
test result notification and counseling guidelines, as
inadeSuate procedures can lead to missed opportuG
nities for prevention and risMGreduction counseling.
Young Incarcerated Men's Perceptions of and
Experiences with HIV Testing.  Kacanek, D. et al.
American Journal of Public Health.  2007;97(7):1-7.
Release from Prison - A High Risk of Death for
Former Inmates
Researchers from the Puget Sound Peterans Affairs
%edical Center recentl; published a retrospective
cohort stud; comparing the risM of death between
all inmates released from the 2ashington State
Department of Corrections between iul; 1999 and
December 2003 and the rest of 2ashington Statejs
residents.  !he stud;, which was published in the
@ew `ngland iournal of %edicine, obtained data on
the 2ashington State residents from the 2ideGrangG
ing Bnbine Data for `pidemiologic Research s;sG
tem of the Centers for Disease Control and
Prevention.  All data was anal;zed using indirect
standardization and was adTusted for age, seN, and
race, so as to prevent the influence of confounding
variables on the stud;js evaluation. 
^ormer inmates were found to have an adTusted risM
of death that was 3.5 times higher than that of the
statejs general populous. In addition, the stud;
revealed that former inmates were at a shocMing
12.Q times higher adTusted risM of death during the
first two weeMs after their release from prison than
other 2ashington State residents. !he leading
causes of death for former inmates were drug overG
dose, cardiovascular disease, homicide, and suiG
cide.  %an; of the deaths linMed to drug overdose
involved cocaine, methamphetamine, heroin, and
methadone, while firearms were involved in man; of
the suicides and homicides.  !he eNcess risM of suiG
cide could be attributable to the prevalence of menG
tal illness in inmates, in combination with the stress
of reentr; and possible lacM of access to mental
health care. Researchers suggest that factors such
as level of education, emplo;ment status, level of
income, neighborhood of residence, and health
insurance status could account for some of the disG
parit; between former inmates and other state resiG
dents, although it is unliMel; that socioeconomic staG
tus could account for all of the variation.  !his stud;
underscores the need for increased planning for the
transition from prison to the communit;, which could
include intensive case management during the periG
od immediatel; following release in order to ensure
that inmates have proper access to medical and
mental health care.
Relase from Prison --- A High Risk of Death for
Former Inmates.  Binswanger, I. Et al.  New
England Journal of Medicine.  2007;356:157-65.
Compiled by Christine Devore, IDCR Intern
NEWS AND LITERATURE REVIEWS
Summer 200Q      Pol. 9, Issue 1Q visit IDCR online at www.IDCRonline.org
SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
!his activit; has been planned and implemented in accordance with the `ssential Areas and Policies of the Accreditation Council for continuing
%edical `ducation through the Toint sponsorship of %edical `ducation Collaborative, Inc. Z%`C[ and IDCR.  %`C is accredited b; the ACC%` to
provide continuing medical education for ph;sicians. 
%edical `ducation Collaborative designates this educational activit; for a maNimum of 1.25 A%A PRA Categor; 1 CreditZs[r.  Ph;sicians should
onl; claim credit commensurate with the eNtent of their participation in the activit;.  Statements of credit will be mailed within 6 to 8 weeMs following
the program. 
e
In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit 
application and evaluation form to the address/fax number indicated.  Statements of credit will be mailed within X-d weeks
following the program.
Please print clearl; as illegible applications will result in a dela;.
@ame: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee  Profession: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
bicense o: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee  State of bicense: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Address: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Cit;: eeeeeeeeeeeeeeeeeeeeeeee State: eeeeeeee sip: eeeeeeeeeeeeeeeeeeeeeeee !elephone: eeeeeeeeeeeeeeeeeee
Please check which credit you are requesting  eee ACC%`   or    eee @on Ph;sicians
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I certify that I participated in IDCR monograph - Summer 2007 Issue     
Please fill in the number of actual hours that ;ou attended this activit;.
Date of participation: eeeeeeeeeeeeeeeeeeeeee  
@umber of *ours ZmaN. 1.25[: eeeeeeeeeeeeeeeeeee
Signature: eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Please Submit Completed Application to:
%edical `ducation Collaborative
651 Corporate Circle, Suite 104, Golden CB 80401
Phone: 303G420G3252 ^Aq: 303G420G3259
^or Suestions regarding the accreditation of this activit;, please call
303G420G3252
Instructions:
k Applications for credit will be accepted until 
iul; 31, 2008.
k bate applications will not be accepted.
k Please anticipate 6G8 weeMs to recieve ;our certificate.
Objectives:
!he learner will understand effective *IP testing policies.
!he learner will understand the challenges to implementing *IP testing in correctional facilities. 
!he learner will understand the new *IP testing policies recommended b; the CDC in 2006. 
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1. According to the authors of the main article, an effective *IP test  
ing polic; upon incarceration is onl; needed if the following *IP 
clinical care services are provided within the correctional facilit; 
after diagnosis:
A. Initiation of *IP antiretroviral therap; for appropriate patients. 
7. A baseline medical evaluation with a determination of CD4n 
count and *IP plasma viral load.
C. Proph;laNis of opportunistic infections
D. Screening for other conditions including viral hepatitis, tuber
culosis, and seNuall; transmitted infections
`. All of the above 
2. 2hich of the following *IP testing policies do the authors of the 
main article supportg
A. %andator; upon entrance or and eNit
7. Poluntar;, optGout, routine testing offered upon entrance 
C. Performed when clinicall; indicated or ordered b; the court
D. 7oth A and C
3. 2hich of the following is @B! cited b; Drs. Paar and 7icM as a 
barrier to implementing routine *IP testing in correctional facilitiesg
A. !he freSuenc; with which incarcerated individuals move from 
facilit; to facilit; and the difficult; of tracMing *IPGpositive indi
viduals through moves
7. `mplo;ing an increased number of preGtest and postGtest 
counselors 
C. `nsuring that ever; *IPGpositive inmate has access to 
providers eNperienced in caring for *IPGpositive patients
D. !he cost of *IP testing and counseling
`. bogisticall; impossible for prisoners to give informed consent
4. All are new *IP testing policies outlined b; the CDCjs new *IP 
testing recommendations from Bctober 2006 `qC`P!:  
A. Screening conducted after notif;ing the patient that an *IP 
test will be performed unless the patient declines ZoptGout 
screening[ is recommended in all healthGcare settings
7. General informed consent for medical care should be consid
ered sufficient to encompass informed consent for *IP testing
C. Prevention counseling reSuired 
D. All of the Above
5. 2hich of the following is @B! cited b; Altice and favaser; as a 
challenge to implementing routine *IP testing in Tailsg 
A. Reluctance of correctional health staff to provide testing and 
treatment for incarcerated individuals 
7. 7earing cost associated with implementing testing and the 
care once *IPGpositive individuals are identified 
C. `nsuring confirmator; testing results for those who test pre
liminaril; positive
D. Choosing the optimal time to conduct testing
10
COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activit; `valuation
^acult;
Content
*ow well did this activit; avoid comG
mercial bias and present content that
was fair and balancedg
2hat is the liMelihood ;ou will
change the wa; ;ou practice based
on what ;ou learned in this activit;g
Bverall, how would ;ou rate 
this activit;g
I5ce//ent Jer$ Kood Kood Fair Moor
II. Course Objectives 
2ere the following overall course obTectives metg  At the conclusion of this presentation, are ;ou able to:
k !he learner will understand effective *IP testing policies. YES NO SOMEWHAT
k !he learner will understand the challenges to implementing *IP testing in correctional facilities. YES NO SOMEWHAT
k !he learner will understand the new *IP testing policies recommended b; the CDC in 2006. YES NO SOMEWHAT
III. Additional luestions
a. Suggested topics and/or speaMers ;ou would liMe for future activities.
b.  Additional Comments 
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